BofA: Investors pour into bonds, pull back from crypto
On Monday, Oppenheimer reiterated its Outperform rating on Artivion Inc. (NYSE: AORT) shares, maintaining a $32.00 price target. The stock has shown remarkable momentum, delivering an 82% return over the past year and currently trading near its 52-week high of $32.33. The reaffirmation follows the recent presentation of one-year follow-up data from Artivion's PERSEVERE study, which evaluated the company's AMDS device in patients with acute DeBakey Type I dissection and malperfusion.
The PERSEVERE study results, presented on Saturday, showcased the AMDS device's effectiveness compared to historic hemiarch repair. The data indicated that stroke occurrence with the use of AMDS was less than half of that in control groups, with a 0% occurrence of DANE tears and evidence of positive aortic remodeling. These findings build upon the positive 30-day data previously released and the announcement in early December that the FDA had granted the AMDS a Humanitarian Device Exemption.
The analysts at Oppenheimer highlighted that the data support the AMDS device's price point of approximately $25,000. With an estimated total addressable market of around 5,000 cases per year across 1,000 U.S. hospitals, the firm anticipates the device will have a significant market impact. According to InvestingPro data, Artivion has demonstrated strong revenue growth of 13.29% in the last twelve months, suggesting solid market execution.
Investors and stakeholders are looking forward to gaining further insights during Artivion's fourth-quarter earnings call, scheduled for February 13, where additional details regarding the AMDS device and its market potential are expected to be discussed. With a strong analyst consensus recommendation and multiple growth catalysts identified by InvestingPro, the positive results from the PERSEVERE study appear to reinforce Oppenheimer's confidence in Artivion's stock performance and its target price for the company.
In other recent news, Artivion Inc. has been granted an FDA exemption for a new aortic dissection device, a significant development in the medical device field. This device, recognized as the first of its kind, has shown a considerable reduction in major adverse events compared to the current standard of care. Artivion's CEO, Pat Mackin, has expressed the company's commitment to making the device accessible to U.S. facilities and physicians.
Artivion also reported a cybersecurity incident, but anticipates no material impact from this event. In the financial sphere, Artivion continues to demonstrate strong performance. Recent developments include a 10% year-over-year increase in revenue to $95.8 million in Q3 2024 and a 28% rise in adjusted EBITDA to $17.7 million. For the full year, Artivion anticipates a revenue growth of 10% to 12%, with projected revenues between $389 million and $396 million.
In addition to these financial developments, Artivion has made progress in regulatory milestones, including the filing of the first module of the AMDS PMA and NMPA approval for BioGlue in China. Analysts from InvestingPro have discussed a $20 million opportunity related to BioGlue in China, with significant progress expected in H2 2025. These recent developments suggest a solid growth trajectory for Artivion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.